menu search

APGE / Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing
Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending positive phase 1 safety and pharmacokinetic data using APG777, the initiation of a 16-week phase 2 study in atopic dermatitis patients is expected in 2024. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Read More
Posted: Aug 22 2023, 08:14
Author Name: Seeking Alpha
Views: 092143

APGE News  

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing

By Seeking Alpha
August 22, 2023

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing

Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending pos more_horizontal

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

By Seeking Alpha
July 15, 2023

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

Following the Independence Day lull, the July IPO market warmed up with two sizable biotechs, joined by two blank check companies. Surf Air Mobility d more_horizontal

Apogee Therapeutics to raise up to $263.1M in IPO

By Proactive Investors
July 11, 2023

Apogee Therapeutics to raise up to $263.1M in IPO

Apogee Therapeutics Inc will offer 15.625 million of its common shares in an initial public offering (IPO) that is expected to be priced between $15 a more_horizontal

IPO Update: Apogee Therapeutics Proposes Terms For $250 Million IPO

By Seeking Alpha
July 10, 2023

IPO Update: Apogee Therapeutics Proposes Terms For $250 Million IPO

Apogee Therapeutics, Inc. has filed proposed terms for a $250 million IPO. The firm is developing drug treatment candidates for atopic dermatitis, COP more_horizontal

Apogee Therapeutics sets IPO terms, to be valued at up to $774.5 mln

By Market Watch
July 10, 2023

Apogee Therapeutics sets IPO terms, to be valued at up to $774.5 mln

Apogee Therapeutics Inc. APGE, has set terms for its initial public offering, as the Massachusetts-based biotechnology company developing treatments f more_horizontal


Search within

Pages Search Results: